

Eugia – Recall of methocarbamol injection

- On March 28, 2024, <u>Eugia announced</u> a consumer-level recall of one lot of <u>methocarbamol</u> injection because of a customer complaint for the presence of white particles floating inside the vial.
- This recalled lot was distributed nationwide from January 12, 2024 and January 16, 2024.

Product Description	NDC number	Lot number (Exp Date)
Methocarbamol injection, 1000 mg/10 mL (100 mg/mL), single dose vial	55150-223-10	3MC23011 (11/2026)

- Methocarbamol injection is used as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.
- Administration of an injectable product that contains particulate matter may result in local irritation
 or swelling. If the particulate matter reaches the blood vessels or is injected intravascularly it can
 travel to various organs and block blood vessels in the heart, lungs or brain which can cause
 stroke and even lead to death.
- To date, Eugia has not received any reports of adverse events related to this recall.
- Anyone with the affected product on hand should discontinue use, stop distribution and quarantine
 product immediately. Patients should contact their healthcare provider if they have experienced
 any problems that may be related to using the recalled product.
- Consumers may contact Eugia by phone at 1-866-850-2876 or by email at pvg@aurobindousa.com for more information.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.